ClinicalTrials.gg
RecruitingNCT05773729Updated Jun 14, 2024

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia

An interventional study of BD211 in β-thalassemia, sponsored by Shanghai BDgene Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-06-14.

Sponsored by Shanghai BDgene Co., Ltd. · Not applicable, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Thalassemia with a site in China — 12 open to participants now, 14 under way, none of them phase 3. Thalassemia · China.

Planned enrollment
21st of 27
10 · median 30
Started
2023
with 1 other
No phase
3 of 32
1 open now
Primary completion
2026-03
later than 3 of 13 live
Registered
21st of 32
by date
Lead sponsor
2 of 32
Shanghai BDgene Co., Ltd.

Among the 32 studies in Thalassemia with a site in China, this one is the 21st largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 21st registered.

Thalassemia

252 studies on the registry are indexed under Thalassemia; 45 are open to participants now.

Browse Thalassemia studies →

Open to participants now

12 of the 32 studies in Thalassemia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Thalassemia studies recruiting now, 8 (28%) set no upper age limit and 18 (62%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Thalassemia with a site in China, or all of them as a file.
02

Study summary

This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.

Read the detailed description

This is an open-label, single-dose study of BD211 in patients with transfusion-dependent β-thalassemia aged 3 to 18 years. It is estimated that 10 subjects will be enrolled. BD211 is a gene modified gene therapy product designed to produce healthy β-globin in red blood cells in beta-thalassemia patients. The total follow-up duration was 24 months, the safe endpoints and effectiveness endpoints will be used to assess the safety and efficacy profiles in patients with transfusion-dependent β-thalassemia.

03

Conditions studied

  • β-thalassemia

Browse trials for

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages 3 to 18 years old, including:

    The parents or legal guardians must be able to understand and provide ICFs. If available, it is strongly recommended that children aged ≥8 years in treatment decisions and obtain written ICFs and be clearly documented; Diagnosed as Transfusion Dependent β-thalassemia with any genotype (β0, β+, βE/β0, βS/S, βS/β0, βS/β+), confirmed the analysis. No alfa chain genetic abnormalities. Subjects must stabilize and maintain an appropriate iron chelation regimen. Transfusion-dependent types are defined as requiring at least 100 mL/kg/ year of red blood cells (pRBCs).

  2. No eligiblity for hematopoietic stem cell transplantation.
  3. The treatment of erythrocyte maturation agent luspatercept cannot be financially supported.
  4. The subjects' parents/legal guardians must be willing and able to follow the study procedures in the study protocol.
  5. Good organs' functions.
  6. Having complete medical records including a history of blood transfusions testified subject received treatment and followed up for at least two years prior to screening .

Exclusion criteria

Exclusion Criteria:

  1. Availability of voluntary, fully HLA-matched hematopoietic cell donors, unless recommended for inclusion by the Monitoring Committee.
  2. -1 and HIV-2 were positive, and / or HTLV-1, HTLV-2 and VSV-G antibodies were positive.
  3. An active bacterial, viral, fungal or parasitic infection.
  4. for the extraction of bone marrow under anesthesia.
  5. Any , myeloproliferative, or immunodeficient disease and relevant medical history.
  6. Peripheral blood white blood cell (WBC) count \< 3×10\^9/L or count \< 120×10\^9/L.
  7. A history of allo-transplantation.
  8. Erythropoietin was used within 3 months prior to HSC cell collection.
  9. Immediate family members with known or suspected familial cancer syndromes (including but not limited to breast, colorectal, ovarian, prostate, and pancreatic cancers).
  10. Subjects with a diagnosis of major mental illness may had a serious disability to participate in the study.
  11. Active recurrent malaria.
  12. Had diseases that may make blood transfusions difficult.
  13. History of major organ injury including:

    Liver disease, transaminase > 3 times the . (If the liver does not reveal evidence of widespread bridging fibrosis, cirrhosis, or acute hepatitis, this indicator will not be used as a criterion for the exclusion); Widely bridging fibrosis, histopathological evidence of acute hepatitis or cirrhosis showed in liver biopsy Heart disease, \< 25%; Kidney disease, \< 30% normal level; Of severe iron overload, confirmed by the study doctor; An heart MRI detection of T2 * \< 10 ms; Significant pulmonary hypertension needing clinical medical intervention.

  14. There are bleeding diseases that have not been cured.
  15. The subject involved with another clinical study in a 30-day screening period.
  16. Allergic to the research drug and its .
  17. Prior treatment with any type of gene and/or cell therapy.
  18. As assessed by the investigator, the subjects or their parents are unable to comply well with the study procedures per protocol.
  19. Hydroxyurea treatment within 3 months prior to hematopoietic stem cell collection.
  20. Had diseases that interfere with hematopoietic stem cells collections.
  21. Any other conditions being ineligible for HSC transplantation determined by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    BD211 Single-Dose group

    Route of Administrate: infusion intravenously. Dosage form: injection solution. Dose: 5×10\^6 cells /kg \~ 10×10\^6 cells /kg. Frequency of administration: One dosing intravenously. Intervention: Single dose of BD211

    Genetic: BD211

Interventions

  • GeneticBD211

    Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.

06

What researchers measure

Primary outcomes

  1. Percentage of treated participants with Transfusion-Dependent β-Thalassemia (TDT) who achieved transfusion independence (TI) for at least 6 months

    TI defined as peripheral blood weighted average hemoglobin (Hb) \> or = 9 g/dL without packed red blood cell (pRBC) transfusion for 60 days after BD211 treatment, and transfusion is continuously halted for 12 months.

    Time frame: 24 months

Secondary outcomes

  1. Hb (g/dL) level between 12 and 24 months after BD211 treatment compared with baseline Hb level

    Hb (g/dL) in 12, 15, 18, 21 and 24 months after drug product infusion are tested and calculated.

    Time frame: 24 months

  2. Parameters of efficacy related to TI achievement after BD211 treatment

    including a. Duration to achieve TI; b. Time from BD211 infusion to last transfusion; c. Time to reach TI from BD211 infusion; d. Mean weighted Hb (g/dL) during TI; and e. Proportion of patients achieving TI at 24 month after BD211 treatment.

    Time frame: 24 months

  3. Parameters of efficacy related to reduced blood transfusion after BD211 treatment

    Including a. Using the transfusion volume from the 2 years prior to the participant's enrollment as a baseline, compared with the transfusion volume between 12 and 24 months after BD211 treatment (mL/kg/month, mL/kg/year), the proportion of participants categorized based on a reduction in transfusion volume of 50%, 75%, 90%, and 100%; b. Using the number of transfusions from the 2 years prior to the participant's enrollment as a baseline, comparing the changes in the volume of pRBC transfusions at 12 and 24 months after BD211 treatment; c. Using the transfusion requirement volume from the 2 years prior to the participant's enrollment as a baseline, comparing the changes in the pRBC transfusion requirement volume at 12 and 24 months after BD211 treatment.

    Time frame: 24 months

  4. Parameters of iron overload after BD211 treatment

    Including a. Time from the last iron-chelation treatment to the last follow-up within 24 months; b. Decrease in serum ferritin level compared from baseline to 6 months and 12 months after BD211 infusion; c. Number and proportion of participants who did not require iron-chelation treatment for at least 6 months after BD211 infusion; d. Comparison of cardiac MRI T2 values at the end of the 24 month after BD211 treatment with the baseline values.

    Time frame: 24 months

  5. Parameters of growth and development after BD211 treatment

    Percentage of pediatric participants reaching the standard for bone age, height, and weight at the same age, at baseline and 24 months after BD211 treatment.

    Time frame: 24 months

  6. Change in quality of life from baseline

    Comparison of Pediatric Quality of Life Inventory (PedQL) scores in pediatric participants at 24 months after BD211 treatment with the scores at baseline.

    Time frame: 24 months

  7. Total hospitalizing days at 12, and 24 months (discharge after transplant)

    Total hospitalizing days at 12, and 24 months after transplantation were counted.

    Time frame: 24 months

  8. Measurement of PD/PK parameters

    Including a. The number and percentage of participants, in whom the HbAT87Q containing the βT87Q-globin remains at or above ≥2.0 g/dL for 6 months or longer, at 18 and 24 months after BD211 infusion; b. Average vector copy number (VCN) of the BD211 lentiviral vector in peripheral blood and bone marrow cells within 24 months after BD211 product infusion; c. Dose-response relationship within 24 months after BD211 infusion.

    Time frame: 24 months

  9. Neutrophil engraftment and platelet engraftment

    Neutrophil engraftment was defined as the first of absolute neutrophil count (ANC) \> or = 0.5 ×10\^9/ L for 3 consecutive days (or 3 consecutive measurements done on separate days), after a post-transplant value less than (\<) 0.5 × 10\^9/L. Platelet engraftment was defined as the first of 3 consecutive platelet values \> or =20 × 10\^9/L for participants on different days with no platelet transfusionsadministered for 7 days immediately preceding. The day of engraftment is the first day of the 3 consecutive platelet measurements.

    Time frame: 24 months

  10. Transplant-related mortality in 3 months and 12 months

    Transplant related mortality was definedas any death occurring in the study post drug product infusion deemed related to the transplant bythe investigator.

    Time frame: 12 months

  11. Overall survival

    Overall survival was defined as time from date of BD211 Drug Product infusion (Day 1) to date of death. Overall survival was censored at the date of last visit if the participant was still alive.

    Time frame: 24 months

  12. RCL incidence

    Subjects blood RCL was detected with specific assay method, and the incidence was calculated at different scheduled timeslots.

    Time frame: 24 months

  13. Characterized insertion mutagenesis events that lead to clonal dominance or leukemia

    The number of insertion mutagenesis events that characterized clonal dominance or leukemia was collected.

    Time frame: 24 months

  14. Frequency and severity of AE

    An AE was any untoward medical occurrence associated with the use of a drug in participants, whether or not considered drug related. An AE may include a change in physical signs, symptoms, and/or clinically significant laboratory change occurring in any phase of a clinical study.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Mar 2026, 30 months after the start.

Of 18 interventional studies with no phase under Thalassemia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 87. This study's planned 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2023
First posted
Mar 17, 2023
StartActual
Sep 15, 2023
Primary completionEst.
Mar 2026
CompletionEst.
Oct 2026
Last update
Jun 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05773729
Lead sponsor
Shanghai BDgene Co., Ltd.
Collaborators
Shanghai Children's Medical Center
Responsible party
Sponsor
First posted
Mar 17, 2023
Start date
Sep 15, 2023
Primary completion
Mar 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jun 14, 2024

Study contacts

Chen Jing, M.D.
Contact
chenjing@scmc.com.cn
+86-18930830632
Chen Jing, M.D.
principal investigator · Shanghai Children's Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion